Skip to main content
SpringerLink
Log in

A rational approach to identifying a fundamentally new drug for the treatment of migraine

  • Chapter
Book cover Cardiovascular Pharmacology of 5-Hydroxytryptamine

Abstract

As early as about AD 50, Aretaeus of Cappadocia is said to have recognised the symptoms of what is now known as migraine, describing the characteristic unilateral headache associated with nausea and symptom-free periods between attacks. More than two thousand years on we still do not understand the aetiology of this often debilitating disease which afflicts up to 10% of the western world. There is however a lot of circumstantial evidence that somehow the ubiquitous, yet until recently almost enigmatic, biogenic amine, 5-hydroxytryptamine (5-HT), is involved.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 39.99
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 54.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Sicuteri F, Testi A, Anselmi B (1961): Biochemical investigations in headache: Increase in the hydroxyindoleacetic acid excretion during migraine attacks. Int Arch Allergy 19: 55–58.

    Article  CAS  Google Scholar 

  2. Anthony M, Hinterberger H, Lance JW (1967): Plasma serotonin in migraine and stress. Arch Neurol 16: 544–552.

    Article  CAS  PubMed  Google Scholar 

  3. Carroll JD, Hilton BP (1974): The effects of reserpine injection on methysergide treated control and migrainous subjects. Headache 14: 149–156.

    Article  CAS  PubMed  Google Scholar 

  4. Fozard JR (1982): Mechanism of the hypotensive effect of ketanserin. J Cardiovasc Pharmacol 4: 829–838.

    Article  CAS  PubMed  Google Scholar 

  5. Graham JR, Wolff HG (1938): Mechanism of migraine headache and action of ergotamine tartrate. Archs Neurol Psychiat, Chicago 39: 737.

    Article  CAS  Google Scholar 

  6. Wolff HG (1963): Headache and other head pain . London: Oxford University Press.

    Google Scholar 

  7. Kimball RW, Friedman AP, Vallejo E (1960): Effect of serotonin in migraine patients. Neurology 10: 107–111.

    Article  CAS  PubMed  Google Scholar 

  8. Lance JW (1973): The mechanism and management of headache . Second Edition, London: Butterworth Publishers.

    Google Scholar 

  9. Lance JW, Anthony M, Somerville B (1970): Comparative trial of serotonin antagonists in the management of migraine. Br Med J 2: 327–330.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  10. Humphrey PPA, Feniuk W, Watts AD (1982): Ketanserin — a novel hypertensive drug? J Pharm Pharmacol 34: 541.

    Article  CAS  PubMed  Google Scholar 

  11. Saxena PR (1974): Selective vasoconstriction in carotid vascular bed by methysergide: Possible relevance to its antimigraine effect. Eur J Pharmacol 27: 99–105.

    Article  CAS  PubMed  Google Scholar 

  12. Saxena PR (1972): The effects of antimigraine drugs on the vascular responses by 5-hydroxytryptamine and related biogenic substances on the external carotid bed of dogs: possible pharmacological implications to their antimigraine action. Headache 12: 44–54.

    Article  CAS  PubMed  Google Scholar 

  13. Apperley E, Humphrey PPA, Levy GP (1976): Receptors for 5-hydroxytryptamine and noradrenaline in rabbit isolated ear artery and aorta. Br J Pharmacol 58: 211–221.

    Article  CAS  PubMed  Google Scholar 

  14. Apperley E, Humphrey PPA, Levy GP (1977): Two types of excitatory receptor for 5-hydroxytryptamine in dog vasculature? Br J Pharmacol 61: 46 50 P.

    Google Scholar 

  15. Apperley E, Feniuk W, Humphrey PPA, Levy GP (1980): Evidence for two types of excitatory receptor for 5-hydroxytryptamine in dog isolated vasculature. Br J Pharmacol 68: 215–224.

    Article  CAS  PubMed  Google Scholar 

  16. Feniuk W, Humphrey PPA, Perren MJ, Watts AD (1985): A comparison of 5-hydroxy- tryptamine receptors mediating contraction in rabbit aorta and dog saphenous vein. Evidence for different receptor types obtained by use of selective agonists and antagonists. Br J Pharmacol 86: 697–704.

    Article  CAS  PubMed  Google Scholar 

  17. Apperley E, Humphrey PPA (1986): The interaction of 5-hydroxytryptamine and methysergide with methiothepin at “5-HT,-like” receptors in dog saphenous vein. Br J Pharmacol 87:13IP.

    Google Scholar 

  18. Gunning SJ, Bunce KT, Humphrey PPA (1988): Methysergide contracts guinea-pig ileum via histamine H1 receptors. Br J Pharmacol 93: 238 P.

    Google Scholar 

  19. Berde B, Schild HO (Eds) (1978): Ergot alkaloids and related compounds . Berlin: Springer-Verlag.

    Google Scholar 

  20. Dalton DW, Feniuk W, Humphrey PPA (1986): An investigation into the mechanisms of the cardiovascular effects of 5-hydroxytryptamine in conscious normotensive and doca- salt hypertensive rats. J Auton Pharmacol 6: 219–228.

    Article  CAS  PubMed  Google Scholar 

  21. Connor HE, Feniuk W, Humphrey PPA, Perren MJ (1986): 5-Carboxamidotryptamine is a selective agonist at 5-hydroxytryptamine receptors mediating vasodilatation and tachycardia in anaesthetized cats. Br J Pharmacol 87:417–426.

    Article  CAS  PubMed  Google Scholar 

  22. Feniuk W, Humphrey PPA, Hunt AAE (1985): The haemodynamic profile and mechanism of the hypotensive action of 5-carboxamidotryptamine in conscious dogs. Br J Pharmacol 85: 31 OP.

    Google Scholar 

  23. Eyre P (1975): Atypical tryptamine receptors in sheep pulmonary vein. Br J Pharmacol 55: 329–333.

    Article  CAS  PubMed  Google Scholar 

  24. Feniuk W, Humphrey PPA, Watts AD (1983): 5-Hydroxytryptamine-induced relaxation of isolated mammalian smooth muscle. Eur J Pharmacol 96:71–78.

    Article  CAS  PubMed  Google Scholar 

  25. Feniuk W, Humphrey PPA, Watts AD (1984): 5-Carboxamido-tryptamine – a potent agonist at 5-hydroxytryptamine receptors mediating relaxation. Br J Pharmacol 82:209P.

    Google Scholar 

  26. Trevethick MA, Feniuk W, Humphrey PPA (1984): 5-Hydroxytryptamine-induced relaxation of neonatal porcine vena cavain vitro. Life Sci 35:477–486.

    Article  CAS  PubMed  Google Scholar 

  27. Trevethick MA, Feniuk W, Humphrey PPA (1986): 5-Carboxamidotryptamine: a potent agonist mediating relaxation and elevation of cyclic AMP in the isolated neonatal porcine vena cava. Life Sci 38:1521–1528.

    Article  CAS  PubMed  Google Scholar 

  28. Sumner MJ, Humphrey PPA, Feniuk W (1987): Characterisation of the 5-HT1-like receptor mediating relaxation of porcine vena cava. Br J Pharmacol 92: 574 P.

    Google Scholar 

  29. Sumner MJ, Feniuk W, Humphrey PPA (1989): Further characterisation of the 5-HT receptor mediating vascular relaxation and elevation of cyclic AMP in isolated porcine vena cava. Br J Pharmacol 97: 292–300.

    Article  CAS  PubMed  Google Scholar 

  30. Bradley PB, Engel G, Feniuk W, Fozard JR, Humphrey PPA, Middlemiss DN, Mylecharane EJ, Richardson BP, Saxena PR (1986): Proposals for the classification and nomenclature of functional receptors for 5-hydroxytryptamine. Neuropharmacology 25: 563–576.

    Article  CAS  PubMed  Google Scholar 

  31. Humphrey PPA (1984): Peripheral 5-hydroxytryptamine receptors and their classification. Neuropharmacology 23: 1503–1510.

    Article  CAS  PubMed  Google Scholar 

  32. Humphrey PPA, Feniuk W (1987): Classification of functional 5-hydroxytryptamine receptors, pp. 277–280 in: Rand MJ, Raper (eds), Pharmacology, International Congress Series 750 (Proceedings of Xth International Congress of Pharmacology – I.U.P.H.A.R.) . Netherlands: Elsevier Science Publishers.

    Google Scholar 

  33. Feniuk W, Humphrey PPA (1989): Mechanisms of 5-hydroxytryptamine-induced vasoconstriction, pp. 100–122, in Fozard JR (ed), The Peripheral Actions of 5-Hydroxy- tryptamine . London: Oxford University Press.

    Google Scholar 

  34. Feniuk W, Humphrey PPA (1989): Mechanisms of 5-hydroxytryptamine-induced vasoconstriction, pp. 100–122, in Fozard JR (ed), The Peripheral Actions of 5-Hydroxy- tryptamine . London: Oxford University Press.

    Google Scholar 

  35. Feniuk W, Humphrey PPA (1989): Mechanisms of 5-hydroxytryptamine-induced vasoconstriction, pp. 100–122, in Fozard JR (ed), The Peripheral Actions of 5-Hydroxy- tryptamine . London: Oxford University Press.

    Google Scholar 

  36. Watts AD, Feniuk W, Humphrey PPA (1981): A pre-junctional action of 5-hydroxytryptamine and methysergide on noradrenergic nerves in dog isolated saphenous vein. J Pharm Pharmacol 33: 515–520.

    Article  CAS  PubMed  Google Scholar 

  37. Feniuk W, Humphrey PPA, Watts AD (1981): Further characterisation of pre- and postjunctional receptors for 5-hydroxytryptamine in isolated vasculature. Br J Pharmacol 73: 191P–192P.

    Google Scholar 

  38. Feniuk W, Humphrey PPA, Watts AD (1981): Modification of the vasomotor actions of methysergide in the femoral arterial bed of the anaesthetised dog by changes in sympathetic nerve activity. J Auton Pharmacol 1: 127–132.

    Article  CAS  PubMed  Google Scholar 

  39. Doenicke A, Siegel E, Hadoke M, Perrin VL (1987): Initial clinical study of AH25086B (5-HT1-like agonist) in the acute treatment of migraine. Cephalalgia 7 (6): 438–439.

    Google Scholar 

  40. Brand J, Hadoke M, Perrin VL (1987): Placebo controlled study of a selective 5-HT1-like agonist, AH25086B, in relief of acute migraine. Cephalalgia 7(6): 402–403.

    Google Scholar 

  41. Humphrey PPA, Feniuk W, Perren MJ, Connor HE, Oxford AW, Coates IH, Butina D (1988): GR43175, a selective agonist for the 5-HT1-like receptor in dog isolated saphenous vein. Br J Pharmacol 94: 1123–1132.

    Article  CAS  PubMed  Google Scholar 

  42. Feniuk W, Humphrey PPA, Perren MJ (1989): The selective carotid arterial vasoconstrictor action of GR43175 in anaesthetised dogs. Br J Pharmacol 96: 83–90.

    Article  CAS  PubMed  Google Scholar 

  43. Perren MJ, Feniuk W, Humphrey PPA (1989): The selective closure of feline carotid arteriovenous anastomoses by GR43175. Cephalalgia 9 (Suppl. 9): 41–46.

    PubMed  Google Scholar 

  44. Humphrey PPA, Perren MJ, Feniuk W, Oxford AW (1989): The pharmacology of the novel 5-HT1-like receptor agonist GR43175. Cephalalgia 9 (Suppl. 9): 23–33.

    PubMed  Google Scholar 

  45. Johnston BM, Saxena PR (1978): The effect of ergotamine on tissue blood flow and the arteriovenous shunting of radioactive microspheres in the head. Br J Pharmacol 63: 541–549.

    Article  CAS  PubMed  Google Scholar 

  46. Neilsen TH, Tfelt-Hansen P (1989): Lack of effect of GR43175 on peripheral arteries in man. Cephalalgia 9 (Suppl. 9): 93–95.

    Google Scholar 

  47. Feniuk W, Humphrey PPA, Perren MJ (1989): GR43175 does not share the complex pharmacology of the ergots. Cephalalgia 9 (Suppl. 9): 35–39.

    PubMed  Google Scholar 

  48. Saxena PR, Bom AH, Verdouw PD (1989): Characterization of 5-hydroxytryptamine receptors in the cranial vasculature. Cephalalgia 9 (Suppl. 9): 15–22.

    PubMed  Google Scholar 

  49. Fozard JR (1987): 5-HT: The enigma variations. Trends Pharmacol Sci 501–506.

    Google Scholar 

  50. Doenicke A, Brand J, Perrin VL (1988): Possible benefit of GR43175, a novel 5-HT1- like receptor agonist, for the acute treatment of severe migraine. Lancet 1: 1309–1311.

    Article  CAS  PubMed  Google Scholar 

  51. Perrin VL, F0ärkkilä M, Goasguen J, Doenicke A, Brand J, Tfelt-Hansen P (1989): Overview of initial clinical studies with intravenous and oral GR43175 in acute migraine. Cephalalgia 9 (Suppl. 9): 63–72.

    PubMed  Google Scholar 

  52. Humphrey PPA, Feniuk W, Perren MJ, Oxford AW, Brittain RT (1989): Sumatriptan Succinate. Drugs of the Future 14 (1): 35–39.

    Google Scholar 

  53. Dallas FAA, Dixon CM, McCulloch RJ, Saynor DA (1989): The kinetics of 14C- GR43175 in rat and dog. Cephalalgia 9 (Suppl. 9): 53–56.

    PubMed  Google Scholar 

  54. Fowler PA, Thomas M, Lacey LF, Andrew P, Dallas FAA (1989): Early studies with the novel 5-HT1-like agonist GR43175 in healthy volunteers. Cephalalgia 9 (Suppl. 9): 57–62.

    PubMed  Google Scholar 

  55. Doenicke A, Melchart D, Bayliss EM (1989): Effective improvement of symptoms in patients with acute migraine with GR43175 dispersible tablets. Cephalalgia 9 (Suppl. 9): 89–92.

    PubMed  Google Scholar 

Download references

Authors
  1. P. P. A. Humphrey
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. E. Apperley
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. W. Feniuk
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. M. J. Perren
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Department of Pharmacology, Erasmus University, Rotterdam, The Netherlands

    P. R. Saxena

  2. Department of Physiology, University of Wales, College of Cardiff, Cardiff, UK

    D. I. Wallis

  3. Department of Pharmacology, Duphar B.V, Weesp, The Netherlands

    W. Wouters  & P. Bevan  & 

Rights and permissions

Reprints and permissions

Copyright information

© 1990 Springer Science+Business Media Dordrecht

About this chapter

Cite this chapter

Humphrey, P.P.A., Apperley, E., Feniuk, W., Perren, M.J. (1990). A rational approach to identifying a fundamentally new drug for the treatment of migraine. In: Saxena, P.R., Wallis, D.I., Wouters, W., Bevan, P. (eds) Cardiovascular Pharmacology of 5-Hydroxytryptamine. Developments in CardioCardiovascular Pharmacology of 5-Hydroxytryptamine, vol 106. Springer, Dordrecht. https://doi.org/10.1007/978-94-009-0479-8_37

Download citation

  • DOI: https://doi.org/10.1007/978-94-009-0479-8_37

  • Publisher Name: Springer, Dordrecht

  • Print ISBN: 978-94-010-6701-0

  • Online ISBN: 978-94-009-0479-8

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics

Search

Navigation